NO971085D0 - Vannopplöselig polymer og peptid modifisert med denne - Google Patents

Vannopplöselig polymer og peptid modifisert med denne

Info

Publication number
NO971085D0
NO971085D0 NO971085A NO971085A NO971085D0 NO 971085 D0 NO971085 D0 NO 971085D0 NO 971085 A NO971085 A NO 971085A NO 971085 A NO971085 A NO 971085A NO 971085 D0 NO971085 D0 NO 971085D0
Authority
NO
Norway
Prior art keywords
water
soluble polymer
peptide modified
modified therewith
therewith
Prior art date
Application number
NO971085A
Other languages
English (en)
Other versions
NO971085L (no
Inventor
David E Wright
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO971085L publication Critical patent/NO971085L/no
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of NO971085D0 publication Critical patent/NO971085D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33303—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group
    • C08G65/33306—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polyamides (AREA)
  • Polyethers (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
NO971085A 1991-10-21 1997-03-10 Vannopplöselig polymer og peptid modifisert med denne NO971085D0 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77979891A 1991-10-21 1991-10-21

Publications (2)

Publication Number Publication Date
NO971085L NO971085L (no) 1993-04-22
NO971085D0 true NO971085D0 (no) 1997-03-10

Family

ID=25117605

Family Applications (2)

Application Number Title Priority Date Filing Date
NO92924060A NO924060L (no) 1991-10-21 1992-10-20 Peg-imidater og proteinderivater derav
NO971085A NO971085D0 (no) 1991-10-21 1997-03-10 Vannopplöselig polymer og peptid modifisert med denne

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO92924060A NO924060L (no) 1991-10-21 1992-10-20 Peg-imidater og proteinderivater derav

Country Status (9)

Country Link
EP (1) EP0539167A3 (no)
JP (2) JP3342060B2 (no)
KR (1) KR100233777B1 (no)
AU (2) AU658231B2 (no)
CA (1) CA2080891A1 (no)
FI (1) FI924747A (no)
NO (2) NO924060L (no)
NZ (1) NZ244778A (no)
ZA (1) ZA928099B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
GB9317618D0 (en) * 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
HU218893B (hu) * 1994-03-31 2000-12-28 Amgen Inc. A megakariocita szaporodás és differenciálódás stimulálására szolgáló módszerek és vízoldható készítmények
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
EP0788375A2 (en) * 1994-11-09 1997-08-13 Robin Ewart Offord Functionalized polymers for site-specific attachment
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
JP2001508783A (ja) * 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー Ｐｅｇ化法
WO1999045026A1 (en) 1998-03-05 1999-09-10 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
AU773891C (en) 1998-10-23 2005-02-17 Kirin-Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
WO2000059926A1 (fr) * 1999-04-02 2000-10-12 Ajinomoto Co., Inc. Procede de production de sous-unite de peptide issue d'une proteine de polymere
BRPI0110914B8 (pt) 2000-05-15 2021-05-25 Hoffmann La Roche 'composição farmacêutica líquida, processo para preparação da mesma e uso de uma composicão farmacêutica'
CN1675242A (zh) * 2002-08-09 2005-09-28 默克专利有限公司 ***中的t－细胞表位
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
AU2003303635B2 (en) * 2002-12-26 2009-07-23 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
US7074755B2 (en) 2003-05-17 2006-07-11 Centocor, Inc. Erythropoietin conjugate compounds with extended half-lives
KR20060032140A (ko) 2003-05-30 2006-04-14 센토코 인코포레이티드 트랜스글루타미나아제를 이용한 신규 에리트로포이에틴접합체의 형성
DE10358213A1 (de) * 2003-12-12 2005-07-28 Clariant Gmbh Polyethylenglykol und dessen Herstellung
ES2460671T3 (es) 2003-12-19 2014-05-14 F. Hoffmann-La Roche Ag Uso de eritropoyetina en el tratamiento de alteraciones de la distribución del hierro en enfermedades intestinales inflamatorias crónicas
EP1773400A2 (en) 2004-07-08 2007-04-18 Amgen Inc. Therapeutic peptides
EP1893240A2 (en) * 2005-06-13 2008-03-05 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
JP2008308690A (ja) * 2007-06-13 2008-12-25 Bio-Cancer Treatment Internatl Ltd ポリ（エチレングリコール）機能性誘導体およびその製造方法
EP2221334B1 (en) * 2007-11-28 2016-12-28 FUJIFILM Corporation Method for chemically modifying biopolymer and polypeptide
CN101455844B (zh) * 2007-12-10 2011-09-14 江苏豪森药业股份有限公司 聚乙二醇化***偶联物和其制备方法与用途
DK3241558T3 (da) 2010-09-28 2021-04-26 Aegerion Pharmaceuticals Inc Højopløselige leptiner
CN116515120B (zh) * 2023-06-07 2024-01-26 中石油(上海)新材料研究院有限公司 一种含三嗪环的聚酰胺弹性体及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
HUT57060A (en) * 1988-12-05 1991-11-28 Biogen Inc Process for producing compositions for inhibiting blood platelet aggregation
WO1992016555A1 (en) * 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers

Also Published As

Publication number Publication date
NO924060D0 (no) 1992-10-20
EP0539167A3 (en) 1993-08-04
FI924747A (fi) 1993-04-22
AU1168495A (en) 1995-06-01
JP3342060B2 (ja) 2002-11-05
KR100233777B1 (ko) 1999-12-01
NO971085L (no) 1993-04-22
NO924060L (no) 1993-04-22
FI924747A0 (fi) 1992-10-20
AU668841B2 (en) 1996-05-16
JPH05214092A (ja) 1993-08-24
NZ244778A (en) 1994-03-25
AU2718392A (en) 1993-04-22
AU658231B2 (en) 1995-04-06
EP0539167A2 (en) 1993-04-28
ZA928099B (en) 1994-04-20
KR930008017A (ko) 1993-05-20
JP2003012697A (ja) 2003-01-15
CA2080891A1 (en) 1993-04-22

Similar Documents

Publication Publication Date Title
NO971085D0 (no) Vannopplöselig polymer og peptid modifisert med denne
NO943511L (no) Farmasöytiske preparater og anvendelse derav
NO944853D0 (no) Glukagonlignende peptid og insulinotropinderivater
DK6893D0 (da) Peptid
NO942066D0 (no) Peptidderivater
NO921012L (no) Farmasoeytiske preparater og deres anvendelse
FI941398A0 (fi) Modifioituja peptidijohdannaisia
FI954559A0 (fi) YY-peptidin analogit ja niiden käytöt
DE69220397D1 (de) Antimikrobielles Peptid und antimikrobieller Wirkstoff
DE69223844D1 (de) Antimikrobielles Peptid und antimikrobieller Wirkstoff
MX9201416A (es) Peptidos y pseudopeptidos antitromboticos.
EP0445801A3 (en) Peptide and its use
GR3031296T3 (en) Cyclic peptides and use thereof
DK197989A (da) Peptidanaloger
BR9202205A (pt) Fibra compensada rigida e lapis
DK650089A (da) Furanalkylketoner og farmaceutiske praeparater deraf
KR900700503A (ko) 펩티드
DK0456138T3 (da) Peptidamidaser og anvendelse deraf
NO971188L (no) Nye PKA-bindingsproteiner og anvendelse derav
NO177858C (no) Peptid
DK703588D0 (da) Pai-1-blokerende peptider, deres fremstilling og anvendelse
DE68914544D1 (de) Peptid und Wirkstoff gegen Dementia.
NO904846D0 (no) Amfifile peptider og anvendelse derav.
NO179907C (no) Benzokinoksaliner og farmasöytiske preparater inneholdende de samme
IT8821191A0 (it) Peptidi anoressizzanti e ipotensivi.